September 6, 2018 Bio/Pharma/CRO

Roche Provides Update on Supplemental Biologics License Application (sBLA) for TECENTRIQ in First-line Metastatic Non-Squamous NSCLC

Basel, 06 September 2018 Roche Provides Update on Supplemental Biologics License Application (sBLA) for TECENTRIQ in First-line Metastatic Non-Squamous NSCLC Roche (SIX: RO, ROG; OTCQX: RHHBY). On September 05 2018, Roche was notified by the U.S. Food and Drug Administration (FDA) that the review period for the supplemental Biologics License Application (sBLA) for TECENTRIQ® (atezolizumab)... Read more

September 6, 2018 Bio/Pharma/CRO

Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC)

Basel, 06 September 2018 Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC) New and updated pivotal data from the TECENTRIQ lung programme, including overall survival (OS) and progression-free survival (PFS) results from Phase III IMpower133 study in extensive-stage small cell lung cancer New... Read more

September 4, 2018 Bio/Pharma/CRO M&A, Partnerships

Pall Corporation and Celltheon Form Strategic Partnership for Biotherapeutics Development and Manufacturing With Celltheon Smart™ Expression Platform

PORT WASHINGTON, NY – September 4, 2018: Pall Corporation, a global leader in filtration, separation and purification, has formed a strategic partnership with Celltheon Corporation, an experienced cell line and expression technology platform development company. This partnership aligns Pall Biotech equipment and consumables with the Celltheon SMART™ Expression Platform to deliver integrated manufacturing solutions for customers developing... Read more

September 3, 2018 Bio/Pharma/CRO PR/Corporate

Reminder: Invitation to Roche's Virtual Late Stage Pipeline Event 2018

Basel, 03 September 2018 Reminder: Invitation to Roche’s Virtual Late Stage Pipeline Event 2018 We are pleased to invite investors and analysts to participate in a live video webcast and conference call on Thursday, 13 September 2018, highlighting development and commercial opportunities within our late stage portfolio.   The Roche Virtual Late Stage Pipeline Event... Read more

August 30, 2018 Bio/Pharma/CRO Product Launch

Positive phase III results for Roche’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine

Basel, 30 August 2018 Positive phase III results for Roche’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis Hemlibra is the first medicine to demonstrate superior efficacy to prior factor VIII prophylaxis based on a statistically significant reduction in... Read more

August 30, 2018 Bio/Pharma/CRO

Positive phase III results for Roche’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine

Basel, 30 August 2018 Positive phase III results for Roche’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis Hemlibra is the first medicine to demonstrate superior efficacy to prior factor VIII prophylaxis based on a statistically significant reduction in... Read more

August 28, 2018 Bio/Pharma/CRO PR/Corporate

Changes to the Roche Corporate Executive Committee

Basel, 28 August 2018 Changes to the Roche Corporate Executive Committee Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Roland Diggelmann, CEO Diagnostics Division and member of the Corporate Executive Committee, will be leaving Roche to pursue his career outside of the company effective 30 September 2018. Until a successor is named, Michael Heuer,... Read more

August 22, 2018 Bio/Pharma/CRO Product Launch

RAPID IDENTIFICATION OF REDOX CYCLING COMPOUNDS – REDOXprofiler™

Dundee, UK – 22nd August 2018: Ubiquigent Limited, a company specializing in providing ubiquitin cell-signalling system drug discovery services, research tools and novel targeted chemistry, announced today that it has launched REDOXprofiler™. The new service, validated following a collaboration with Medivir AB, enables the rapid identification of REDOX cycling compounds (RCCs), which may generate false... Read more

August 20, 2018 Atomic Spectroscopy Bio/Pharma/CRO Molecular Spectroscopy

HORIBA Boosts Development and Production of Optical Analysis and Measurement Instruments in the U.S.

August 20, 2018 HORIBA New Jersey Optical Spectroscopy Center to Open HORIBA, Ltd. (Head Office: Kyoto, Japan; hereinafter, “HORIBA”) announced today the relocation of its development and production center for optical analysis and measurement instruments. The relocation will take place within the U.S. state of New Jersey, moving from Edison to Piscataway, with the Center... Read more

August 20, 2018 Bio/Pharma/CRO Liq. Handling & Robotics Process Analytical Instr.

Unchained Labs just couldn’t take it anymore, frees the Big Kahuna!

August 20, 2018 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, renamed its flagship workflow solution today. Freeslate is now the Big Kahuna. “We really love this product and it deserved to be a part of the Unchained Labs family,” said Taegen Clary, VP... Read more